In a report released yesterday, Luca Issi from RBC Capital maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report), with a price target of $50.00. The company’s shares closed yesterday at $24.72.
According to TipRanks, Issi is an analyst with an average return of -22.8% and a 19.80% success rate. Issi covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Moderna, and BioMarin Pharmaceutical.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arrowhead Pharmaceuticals with a $63.25 average price target, representing a 155.87% upside. In a report released on May 3, Piper Sandler also reiterated a Buy rating on the stock with a $62.00 price target.
ARWR market cap is currently $3.06B and has a P/E ratio of -8.92.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ARWR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arrowhead Pharmaceuticals (ARWR) Company Description:
Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
Read More on ARWR:
